Cancer and its treatment are associated with several long term complications. While most therapeutic modalities for cancer are beneficial and lifesaving, they are associated with adverse long-term and late sequelae including systemic symptoms like fatigue, frailty, premature onset of lifestyle diseases, musculoskeletal, endocrine, cardiovascular, neurologic and second cancers. As survival rates for cancer improve, we are faced with challenges in the long term care of these patients and new approaches to provide equitable care for these complex patients are warranted. This is even more important in the context of newer cancer therapies, as cancer treatments evolve to include targeted and immunotherapies.
Cancer survivors face long term morbidity and excess mortality, derived from both the direct effects of cancer treatment and the accumulation of chronic health conditions. Most therapeutic modalities for cancer are associated with a spectrum of late complications, which can range from minor symptoms to potentially lethal conditions. The impact of sociodemographics, life style factors and comorbidities on a cancer survivor's health and their possible interaction with the risk for severe late complications is unknown. There is also limited information regarding the incidence and prevalence of these late effects, and it is important to examine the role of a healthy lifestyle and health promotion in ameliorating adverse treatment related consequences. There are few evidence-based guidelines or recommendations for managing long-term and late effects of cancer survivors. Studies on pathogenesis of these complications, biomarkers (genetic, epigenetic, non-genetic), risk prediction modeling of late effects and effective strategies to mitigate the risk of chronic health conditions in this population are warranted. There is also studies examining the impact of survivorship on health care utilization, appropriate follow up care and surveillance for survivors.
This Research Topic aims to highlight the latest research in cancer survivorship to increase awareness about late complications of cancer and its treatment, particularly focusing on risk prediction of cardiovascular complications, neuro-cognitive outcomes and second malignancies. We encourage submission of original articles related to these outcomes, and also review articles that describe the current state of research in these areas. Side effects of novel cancer therapies such as targeted agents and immunotherapy are also welcome.
Topics of interest include but not limited to:
1. Long term complications of cancer treatments, particularly from novel cancer therapies
2. Precision medicine applications in cancer survivors
3. Pathogenesis of late complications in cancer survivors
4. Interventions to alleviate the morbidity and mortality in cancer survivors
5. Machine learning applications for cancer outcomes risk prediction
Cancer and its treatment are associated with several long term complications. While most therapeutic modalities for cancer are beneficial and lifesaving, they are associated with adverse long-term and late sequelae including systemic symptoms like fatigue, frailty, premature onset of lifestyle diseases, musculoskeletal, endocrine, cardiovascular, neurologic and second cancers. As survival rates for cancer improve, we are faced with challenges in the long term care of these patients and new approaches to provide equitable care for these complex patients are warranted. This is even more important in the context of newer cancer therapies, as cancer treatments evolve to include targeted and immunotherapies.
Cancer survivors face long term morbidity and excess mortality, derived from both the direct effects of cancer treatment and the accumulation of chronic health conditions. Most therapeutic modalities for cancer are associated with a spectrum of late complications, which can range from minor symptoms to potentially lethal conditions. The impact of sociodemographics, life style factors and comorbidities on a cancer survivor's health and their possible interaction with the risk for severe late complications is unknown. There is also limited information regarding the incidence and prevalence of these late effects, and it is important to examine the role of a healthy lifestyle and health promotion in ameliorating adverse treatment related consequences. There are few evidence-based guidelines or recommendations for managing long-term and late effects of cancer survivors. Studies on pathogenesis of these complications, biomarkers (genetic, epigenetic, non-genetic), risk prediction modeling of late effects and effective strategies to mitigate the risk of chronic health conditions in this population are warranted. There is also studies examining the impact of survivorship on health care utilization, appropriate follow up care and surveillance for survivors.
This Research Topic aims to highlight the latest research in cancer survivorship to increase awareness about late complications of cancer and its treatment, particularly focusing on risk prediction of cardiovascular complications, neuro-cognitive outcomes and second malignancies. We encourage submission of original articles related to these outcomes, and also review articles that describe the current state of research in these areas. Side effects of novel cancer therapies such as targeted agents and immunotherapy are also welcome.
Topics of interest include but not limited to:
1. Long term complications of cancer treatments, particularly from novel cancer therapies
2. Precision medicine applications in cancer survivors
3. Pathogenesis of late complications in cancer survivors
4. Interventions to alleviate the morbidity and mortality in cancer survivors
5. Machine learning applications for cancer outcomes risk prediction
